SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gambi, F.
Right arrow Articles by Ferro, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gambi, F.
Right arrow Articles by Ferro, F. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study

Francesco Gambi

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy, fgambi{at}unich.it

Domenico De Berardis

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Daniela Campanella

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Alessandro Carano

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Gianna Sepede

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Gabriele Salini

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Daniela Mezzano

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Alessandra Cicconetti

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Laura Penna

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Rosa Maria Salerno

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Filippo Maria Ferro

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score 7. At 12 weeks, response was achieved by 79.5% of the patients (n 35) and remission by 36.4% of patients (n 16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.

Key Words: mirtazapine • generalized anxiety disorder • open label • pharmacotherapy

Journal of Psychopharmacology, Vol. 19, No. 5, 483-487 (2005)
DOI: 10.1177/0269881105056527


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
J. Davidson, W. Zhang, K. Connor, J. Ji, K. Jobson, Y. Lecrubier, A. McFarlane, D. Newport, D. Nutt, D. Osser, et al.
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
J Psychopharmacol, January 1, 2010; 24(1): 3 - 26.
[Abstract] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. Singh, P. Ghazvini, N. Robertson, A. J. Massey, O. Kirksey, and M. S. Honeywell
Sleep Disturbances in Patients With Psychiatric Illnesses
Journal of Pharmacy Practice, December 1, 2006; 19(6): 369 - 378.
[Abstract] [PDF]



Advertisement